Vaxart Inc Stock Buy Hold or Sell Recommendation
| VXRT Stock | USD 0.84 0.03 3.45% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Vaxart Inc is 'Strong Sell'. Macroaxis provides Vaxart buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding Vaxart positions. The advice algorithm takes into account all of Vaxart's available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Vaxart's buy or sell advice are summarized below:
Real Value 1.75 | Target Price 4.5 | Hype Value 0.83 | Market Value 0.84 | Naive Value 0.69 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Vaxart Inc given historical horizon and risk tolerance towards Vaxart. When Macroaxis issues a 'buy' or 'sell' recommendation for Vaxart Inc, the advice is generated through an automated system that utilizes algorithms and statistical models.
Vaxart |
Execute Vaxart Buy or Sell Advice
The Vaxart recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Vaxart Inc. Macroaxis does not own or have any residual interests in Vaxart Inc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Vaxart's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Vaxart Trading Alerts and Improvement Suggestions
| Vaxart Inc had very high historical volatility over the last 90 days | |
| Vaxart Inc has some characteristics of a very speculative penny stock | |
| Vaxart Inc has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 7.38 M. Net Loss for the year was (82.47 M) with loss before overhead, payroll, taxes, and interest of (80.95 M). | |
| Vaxart Inc currently holds about 129.55 M in cash with (70.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.02, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3 |
Vaxart Returns Distribution Density
The distribution of Vaxart's historical returns is an attempt to chart the uncertainty of Vaxart's future price movements. The chart of the probability distribution of Vaxart daily returns describes the distribution of returns around its average expected value. We use Vaxart Inc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Vaxart returns is essential to provide solid investment advice for Vaxart.
| Mean Return | 0.36 | Value At Risk | -7.5 | Potential Upside | 7.41 | Standard Deviation | 5.20 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Vaxart historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Vaxart Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Vaxart is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Vaxart Inc backward and forwards among themselves. Vaxart's institutional investor refers to the entity that pools money to purchase Vaxart's securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bank Of America Corp | 2023-12-31 | 176 K | Charles Schwab Investment Management Inc | 2023-12-31 | 153.5 K | Private Portfolio Partners Llc | 2023-12-31 | 103.2 K | Group One Trading, Lp | 2023-12-31 | 82.8 K | Dimensional Fund Advisors, Inc. | 2023-12-31 | 79.1 K | T. Rowe Price Associates, Inc. | 2023-12-31 | 78.5 K | Susquehanna International Group, Llp | 2023-12-31 | 78.1 K | Hbk Sorce Advisory Llc | 2023-12-31 | 75.1 K | Ae Wealth Management Llc | 2023-12-31 | 62.2 K | Vanguard Group Inc | 2023-12-31 | 7 M | Geode Capital Management, Llc | 2023-12-31 | 2 M |
Vaxart Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 2.0M | 113.3M | 16.9M | (97.7M) | (11.3M) | (10.7M) | |
| Free Cash Flow | (13.9M) | (25.0M) | (65.0M) | (104.4M) | (72.3M) | (68.7M) | |
| Depreciation | 3.6M | 2.7M | 4.2M | 5.8M | 4.5M | 3.5M | |
| Other Non Cash Items | (1.3M) | (1.4M) | (3.4M) | (5.8M) | 32.8M | 34.4M | |
| Capital Expenditures | 850K | 1.2M | 5.2M | 9.6M | 1.9M | 1.8M | |
| Net Income | (18.6M) | (32.2M) | (70.5M) | (107.8M) | (82.5M) | (78.3M) | |
| End Period Cash Flow | 13.5M | 126.9M | 143.7M | 46.0M | 34.8M | 53.6M | |
| Investments | (850K) | (1.2M) | (39.1M) | (10.8M) | 44.0M | 46.1M | |
| Change Receivables | (1.8M) | 3.3M | 263K | 51K | 58.7K | 55.7K | |
| Change To Netincome | 814K | 4.4M | 11.9M | 17.8M | 20.5M | 21.5M |
Vaxart Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Vaxart or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Vaxart's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Vaxart stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.28 | |
β | Beta against NYSE Composite | 1.22 | |
σ | Overall volatility | 5.16 | |
Ir | Information ratio | 0.06 |
Vaxart Volatility Alert
Vaxart Inc shows above-average downside volatility for the selected time horizon. Vaxart Inc is a potential penny stock. Although Vaxart may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Vaxart Inc. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Vaxart instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Vaxart Fundamentals Vs Peers
Comparing Vaxart's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Vaxart's direct or indirect competition across all of the common fundamentals between Vaxart and the related equities. This way, we can detect undervalued stocks with similar characteristics as Vaxart or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Vaxart's fundamental indicators could also be used in its relative valuation, which is a method of valuing Vaxart by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Vaxart to competition |
| Fundamentals | Vaxart | Peer Average |
| Return On Equity | -0.98 | -0.31 |
| Return On Asset | -0.42 | -0.14 |
| Operating Margin | (5.21) % | (5.51) % |
| Current Valuation | 133.24 M | 16.62 B |
| Shares Outstanding | 173.86 M | 571.82 M |
| Shares Owned By Insiders | 0.96 % | 10.09 % |
| Shares Owned By Institutions | 18.15 % | 39.21 % |
| Number Of Shares Shorted | 17.19 M | 4.71 M |
| Price To Book | 2.75 X | 9.51 X |
| Price To Sales | 21.44 X | 11.42 X |
| Revenue | 7.38 M | 9.43 B |
| Gross Profit | (80.95 M) | 27.38 B |
| EBITDA | (78.85 M) | 3.9 B |
| Net Income | (82.47 M) | 570.98 M |
| Cash And Equivalents | 129.55 M | 2.7 B |
| Cash Per Share | 1.02 X | 5.01 X |
| Total Debt | 26.51 M | 5.32 B |
| Debt To Equity | 0.09 % | 48.70 % |
| Current Ratio | 8.65 X | 2.16 X |
| Book Value Per Share | 0.38 X | 1.93 K |
| Cash Flow From Operations | (70.45 M) | 971.22 M |
| Short Ratio | 10.91 X | 4.00 X |
| Earnings Per Share | (0.57) X | 3.12 X |
| Target Price | 5.0 | |
| Number Of Employees | 109 | 18.84 K |
| Beta | 0.56 | -0.15 |
| Market Capitalization | 146.44 M | 19.03 B |
| Total Asset | 91.83 M | 29.47 B |
| Retained Earnings | (409.57 M) | 9.33 B |
| Working Capital | 31.81 M | 1.48 B |
| Net Asset | 91.83 M |
Note: Acquisition by Phillip Lee of 410000 shares of Vaxart at 0.78 subject to Rule 16b-3 [view details]
Vaxart Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Vaxart . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Vaxart Buy or Sell Advice
When is the right time to buy or sell Vaxart Inc? Buying financial instruments such as Vaxart Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 13.0M | 21.7M | 26.5M | 28.4M | Total Assets | 221.2M | 153.8M | 91.8M | 150.6M |
Use Investing Ideas to Build Portfolios
In addition to having Vaxart in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Construction Materials Thematic Idea Now
Construction Materials
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Construction Materials theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Construction Materials Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Vaxart Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for Vaxart Stock analysis
When running Vaxart's price analysis, check to measure Vaxart's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxart is operating at the current time. Most of Vaxart's value examination focuses on studying past and present price action to predict the probability of Vaxart's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxart's price. Additionally, you may evaluate how the addition of Vaxart to your portfolios can decrease your overall portfolio volatility.
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments |
Is Vaxart's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vaxart. If investors know Vaxart will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vaxart listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.57) | Revenue Per Share 0.051 | Quarterly Revenue Growth 146.5 | Return On Assets (0.42) | Return On Equity (0.98) |
The market value of Vaxart Inc is measured differently than its book value, which is the value of Vaxart that is recorded on the company's balance sheet. Investors also form their own opinion of Vaxart's value that differs from its market value or its book value, called intrinsic value, which is Vaxart's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vaxart's market value can be influenced by many factors that don't directly affect Vaxart's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vaxart's value and its price as these two are different measures arrived at by different means. Investors typically determine if Vaxart is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vaxart's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.